The FDA approved the first PrEP drug, Truvada, in 2012.
AP Photo/Jeff Chiu
World AIDS Day on Dec. 1 this year comes at a time when a key step to removing financial barriers to PrEP access in the U.S. faces legal challenges.
Long-acting cabotegravir injections once every eight weeks was better than the daily tablet used for HIV prevention.
Our findings suggest that cabotegravir is much more effective than Truvada in preventing HIV infection in women.
Facebook recently disabled some ads on its site making dubious claims about Truvada.
AP Photo/Rich Pedroncelli
Facebook began blocking ads that linked Truvada and other HIV-related drugs to severe bone and kidney damage based on claims made in lawsuits.
It’s unrealistic to expect everyone who is sexually active will take perfect preventative measures.
An increase in condomless sex in PrEP users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
Australia is within reach of achieving its pledge to end new HIV transmissions by 2020.
The HIV prevention drug Truvada (PrEP) will be listed on the Pharmaceutical Benefits Scheme from this Sunday, moving Australia closer to achieving its goal of ending new HIV transmissions by 2020.
PrEP drugs are not a perfect solution.
PrEP may be giving some homosexual and heterosexual users a false sense of security.
If the vaginal ring becomes available for commercial use it will become one of the tools in the HIV prevention toolbox for women alongside female condoms and daily pre-exposure prophylaxis.
PrEP is a game-changer for couples where one person is HIV positive, allowing natural conception with minimal risk.
A new pill available could enable people living with HIV to conceive children through sex without risking the health of their HIV-negative partner.
Making waves but will it cross the pond?
The latest report from Public Health England revealed that there were more than 100,000 people living with HIV in the UK, with 6,000 new infections last year. Around a quarter of people are unaware they…